Epigenomic evolution in diffuse large B-cell lymphomas.

Epigenomic evolution in diffuse large B-cell lymphomas.
复制标题

DOI:
10.1038/ncomms7921
复制
发表时间:
2015-04-20
影响因子:
16.6
通讯作者:
Elemento, Olivier
Elemento, Olivier
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Pan, Heng;Jiang, Yanwen;Boi, Michela;Tabbo, Fabrizio;Redmond, David;Nie, Kui;Ladetto, Marco;Chiappella, Annalisa;Cerchietti, Leandro;Shaknovich, Rita;Melnick, Ari M.;Inghirami, Giorgio G.;Tam, Wayne;Elemento, Olivier

文献摘要

参考文献

被引文献

相似文献

表观基因组改变对肿瘤进展和复发的贡献还没有得到很好的表征。在这里,我们描述了弥漫性大B细胞淋巴瘤(DLBCL)的疾病进展和DNA甲基化之间的关系。通过在13个DLBCL诊断-复发样本对中以单碱基对分辨率分析全基因组DNA甲基化,我们表明DLBCL患者在复发期间表现出肿瘤甲基化组的异质性演变。我们鉴定了差异甲基化的调控元件,并确定了与转化生长因子-β(TGF-β)受体活性等关键通路会聚的复发相关甲基化特征。我们还观察到从诊断到复发肿瘤样品的肿瘤内甲基化异质性降低。在独立验证队列中,与复发患者相比,无复发患者在诊断时显示出较低的肿瘤内甲基化异质性。此外,肿瘤内甲基化异质性可预测复发时间。因此,我们提出表观基因组异质性可能支持或驱动复发表型,并可用于预测DLBCL复发。 表观基因组改变对肿瘤进展和复发的贡献还没有得到很好的表征。在这里,作者描述了侵袭性B细胞淋巴瘤的表观遗传进化,并发现表观基因组异质性不仅可以支持和驱动复发表型,还可以用于预测淋巴瘤复发。
The contribution of epigenomic alterations to tumour progression and relapse is not well characterized. Here we characterize an association between disease progression and DNA methylation in diffuse large B-cell lymphoma (DLBCL). By profiling genome-wide DNA methylation at single-base pair resolution in thirteen DLBCL diagnosis–relapse sample pairs, we show that DLBCL patients exhibit heterogeneous evolution of tumour methylomes during relapse. We identify differentially methylated regulatory elements and determine a relapse-associated methylation signature converging on key pathways such as transforming growth factor-β (TGF-β) receptor activity. We also observe decreased intra-tumour methylation heterogeneity from diagnosis to relapsed tumour samples. Relapse-free patients display lower intra-tumour methylation heterogeneity at diagnosis compared with relapsed patients in an independent validation cohort. Furthermore, intra-tumour methylation heterogeneity is predictive of time to relapse. Therefore, we propose that epigenomic heterogeneity may support or drive the relapse phenotype and can be used to predict DLBCL relapse. The contribution of epigenomic alterations to tumour progression and relapse is not well characterized. Here the authors characterize epigenetic evolution in aggressive B-cell lymphoma and find that epigenomic heterogeneity may not only support and drive the relapse phenotype but also be used to predict lymphoma relapse.
DOI: 10.1158/2159-8290.cd-13-0117
发表时间: 2013-09
期刊: Cancer discovery
影响因子: 28.2
作者:
Clozel T;Yang S;Elstrom RL;Tam W;Martin P;Kormaksson M;Banerjee S;Vasanthakumar A;Culjkovic B;Scott DW;Wyman S;Leser M;Shaknovich R;Chadburn A;Tabbo F;Godley LA;Gascoyne RD;Borden KL;Inghirami G;Leonard JP;Melnick A;Cerchietti L
通讯作者: Cerchietti L
深度测序揭示了与 B 细胞淋巴瘤复发相关的克隆进化模式和突变事件。
DOI: 10.1186/s13059-014-0432-0
发表时间: 2014-08-15
期刊: Genome biology
影响因子: 12.3
作者:
Jiang Y;Redmond D;Nie K;Eng KW;Clozel T;Martin P;Tan LH;Melnick AM;Tam W;Elemento O
通讯作者: Elemento O
DOI: 10.1038/ng.2442
发表时间: 2012-11-01
期刊: NATURE GENETICS
影响因子: 30.8
作者:
Landan, Gilad;Cohen, Netta Mendelson;Tanay, Amos
通讯作者: Tanay, Amos
DOI: 10.1016/j.molcel.2009.11.016
发表时间: 2009-12-11
期刊: Molecular cell
影响因子: 16
作者:
Goodarzi H;Elemento O;Tavazoie S
通讯作者: Tavazoie S
DOI: 10.1043/1543-2165(2008)132
发表时间: 2008-07-01
影响因子: 4.6
作者:
AuBuchon, J. P.;de Wildt-Eggen, J.;Dumont, L. J.
通讯作者: Dumont, L. J.